# OnCo record beamion-lung-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/beamion-lung-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "beamion-lung-1", "NCT04886804" ;
  schema:name "Beamion LUNG-1"@en ;
  schema:description "Beamion LUNG-1 showed that zongertinib, a pill that blocks mutant HER2 while sparing EGFR, shrinks about seven in ten HER2-mutant lung cancers after chemotherapy, and it became the first oral HER2 drug approved for lung cancer."@en ;
  schema:url <https://onco.cc/trials/beamion-lung-1/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04886804>, <https://doi.org/10.1056/NEJMoa2503704> ;
  onco:status "positive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/her2-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/boehringer-ingelheim/> ;
  onco:terms <https://onco.cc/terms/hepatotoxicity/> ;
  onco:people <https://onco.cc/people/john-heymach/> .